Salivary Chloride Intracellular Channel 1 (CLIC1) as a Hub of Gene-Gene Interactome of Periodontitis With Diabetes Mellitus.

Background and introduction Periodontal disease is one of the most prevalent chronic conditions that affects the oral cavity. Identifying and predicting biomarkers is essential for the prevention of high-morbidity oral diseases. The genomic interaction network identifies common hub genes involved in crucial protein formation in periodontal inflammation. Diabetes mellitus is a metabolic disorder that has a double-edged sword relationship with periodontitis. Chloride intracellular channel 1 (CLIC1) was identified as a hub gene linking the pathogenesis of periodontitis and diabetes mellitus using a bioinformatic tool. Therefore, this current study aimed to assess the concentration of the pro-inflammatory biomarker CLIC1 in saliva among individuals with periodontal health and those with periodontal disease linked to diabetes mellitus. Materials and methods Differentially expressed genes (DEGs) in periodontitis were identified using datasets retrieved from the Gene Expression Omnibus (GEO) database. DEGs were combined to build the network, and GeneMANIA was used to find and rank the interconnecting genes. CLIC1 was identified as the hub gene, and clinical validation was done using patient samples. The study involved 30 participants. Based on clinical and radiographic periodontal findings, they were split into three groups: healthy (group 1, n=10), with periodontitis but no diabetes mellitus (group 2, n=10), and with periodontitis and diabetes mellitus (group 3, n=10). The collection of saliva samples, followed by quantifying these samples, was performed using an enzyme-linked immunosorbent assay (ELISA). Results From network graph analysis, it was discovered that CLIC1 functions as a hub gene in the majority of toll-like receptor pathways. The mean concentration of CLIC1 in saliva increased consistently as the disease was observed in periodontitis patients and periodontitis patients with diabetes mellitus.  Conclusion CLIC1 concentrations were positively correlated with periodontitis in individuals with diabetes. Therefore, CLIC1 could be a diagnostic biomarker for patients with periodontitis. However, large-scale studies are needed to confirm more positive associations.

Comprehensive profiling of the VOCs of Trichoderma longibrachiatum EF5 while interacting with Sclerotium rolfsii and Macrophomina phaseolina.

Trichoderma longibrachiatum EF5 is an endophytic fungal antagonist of rice. It is used for the control of soil-borne fungal pathogens-Sclerotium rolfsii and Macrophomina phaseolina. We demonstrate that T. longibrachiatum EF5 inhibits the growth of these pathogens on direct interaction as well as via the production of the microbial volatile organic compounds (mVOCs). The mVOCs reduced mycelial growth and inhibited the production of sclerotia by altering the mycelial structure. We profiled 138 mVOCs, when T. longibrachiatum EF5 interacted with the two pathogens. During these interactions, several compounds are up- or downregulated by T. longibrachiatum EF5, including longifolene, caryophyllene,1-Butanol 2-methyl, cedrene, and cuprenene. These compounds are involved in the biosynthetic pathways of the sesquiterpenoid and alkane, and the degradation pathway of trimethylamine. We provide an insight into the multiple modes by which T. longibrachiatum EF5 exerts antagonistic actions, such as hyperparasitism, competitions, and antibiosis via mVOCs. In contrast to their antimicrobial properties, these metabolites could also promote plant growth.

Safety Profile and Therapeutic Efficacy of One Cycle of Lu177-PSMA in End-Stage Metastatic Castration-Resistant Prostate Cancer Patients with Low Performance Status / 대한핵의학회잡지

PURPOSE@#The aim of this study was to evaluate safety and therapeutic efficacy of lutetium 177 prostate-specific membrane antigen (Lu-177-PSMA) in metastatic castration-resistant prostate cancer (mCRPC) patients with low performance status.@*METHODS@#Twenty-two patients already treated with anti-androgens and docetaxel were enrolled for one cycle of Lu-177-PSMA therapy. Haemoglobin, total leukocyte counts, platelets and serum creatinine for toxicity profile while prostate specific antigen (PSA), Eastern Cooperative Oncology Group (ECOG) performance status, visual analogue scale (VAS) and analgesic quantification scale (AQS) for therapeutic efficacy were recorded pre and 8 weeks post therapy. Wilcoxon signed-rank and ANOVA tests were used for statistical analysis.@*RESULTS@#Partial response (PR), stable disease (SD) and progressive disease (PD) for PSAwere seen in 5 (22.7%), 13 (59.1%) and 4 (18.2%) patients respectively treated with mean 6.88 GBq dose of Lu-177-PSMA. 8/22 (36.4%) patients showed ≥ 30% drop in PSA. Grade 3 haemoglobin toxicity was seen in 5/22 (22.7%) patients. No patient developed grade 4 haemoglobin toxicity. No patients had grade 3 or 4 leukocytopenia or thrombocytopenia. Wilcoxon signed-rank test showed statistical significant (P < 0.05) difference in pre and post treatment ECOG, VAS, and AQS scores. The ANOVA test showed statistically significant difference in mean doses of Lu-177-PSMA used in three PSA response groups while difference was non-significant for other variables.@*CONCLUSION@#We concluded that Lu-177-PSMA therapy has adequate pain palliation in end-stage mCRPC patients with low performance status and it has a potential to become effective therapeutic option in properly selected patients.

Safety Profile and Therapeutic Efficacy of One Cycle of Lu177-PSMA in End-Stage Metastatic Castration-Resistant Prostate Cancer Patients with Low Performance Status / 대한핵의학회잡지

PURPOSE: The aim of this study was to evaluate safety and therapeutic efficacy of lutetium 177 prostate-specific membrane antigen (Lu-177-PSMA) in metastatic castration-resistant prostate cancer (mCRPC) patients with low performance status.METHODS: Twenty-two patients already treated with anti-androgens and docetaxel were enrolled for one cycle of Lu-177-PSMA therapy. Haemoglobin, total leukocyte counts, platelets and serum creatinine for toxicity profile while prostate specific antigen (PSA), Eastern Cooperative Oncology Group (ECOG) performance status, visual analogue scale (VAS) and analgesic quantification scale (AQS) for therapeutic efficacy were recorded pre and 8 weeks post therapy. Wilcoxon signed-rank and ANOVA tests were used for statistical analysis.RESULTS: Partial response (PR), stable disease (SD) and progressive disease (PD) for PSAwere seen in 5 (22.7%), 13 (59.1%) and 4 (18.2%) patients respectively treated with mean 6.88 GBq dose of Lu-177-PSMA. 8/22 (36.4%) patients showed ≥ 30% drop in PSA. Grade 3 haemoglobin toxicity was seen in 5/22 (22.7%) patients. No patient developed grade 4 haemoglobin toxicity. No patients had grade 3 or 4 leukocytopenia or thrombocytopenia. Wilcoxon signed-rank test showed statistical significant (P < 0.05) difference in pre and post treatment ECOG, VAS, and AQS scores. The ANOVA test showed statistically significant difference in mean doses of Lu-177-PSMA used in three PSA response groups while difference was non-significant for other variables.CONCLUSION: We concluded that Lu-177-PSMA therapy has adequate pain palliation in end-stage mCRPC patients with low performance status and it has a potential to become effective therapeutic option in properly selected patients.

A Randomized Controlled Study to Compare the Total and Hidden Blood Loss in Computer-Assisted Surgery and Conventional Surgical Technique of Total Knee Replacement

BACKGROUND: Total knee arthroplasty (TKA) is associated with considerable blood loss. Computer-assisted surgery (CAS) is different from conventional TKA as it avoids opening the intramedullary canal. Hence, CAS should be associated with less blood loss. METHODS: Fifty-seven patients were randomized into two groups of CAS and conventional TKA. In conventional group intramedullary femoral and extramedullary tibial jigs were used whereas in CAS group imageless navigation system was used. All surgeries were done under tourniquet. Total and hidden blood loss was calculated in both groups and compared. RESULTS: The mean total blood loss was 980 mL in conventional group and 970 mL in CAS group with median of 1,067 mL (range, 59 to 1,791 mL) in conventional group and 863 mL (range, 111 to 2,032 mL) in CAS group. There was no significant difference in total blood loss between the two groups (p = 0.811). We have found significant hidden blood loss in both techniques, which is 54.8% of the total loss in the conventional technique and 59.5% in the computer-assisted navigation technique. CONCLUSIONS: There is no significant difference in total and hidden blood loss in the TKA in CAS and conventional TKA. However, there is significant hidden blood loss in both techniques. There was no relation of tourniquet time with blood loss.